Discovery of Novel Inhibitors against ALS-Related SOD1(A4V) Aggregation through the Screening of a Chemical Library Using Differential Scanning Fluorimetry (DSF)
Open Access
- 27 September 2024
- journal article
- research article
- Published by MDPI AG in Pharmaceuticals
- Vol. 17 (10) , 1286
Abstract
Background: Cu/Zn Superoxide Dismutase 1 (SOD1) is a 32 kDa cytosolic dimeric metalloenzyme that neutralizes superoxide anions into oxygen and hydrogen peroxide. Mutations in SOD1 are associated with ALS, a disease causing motor neuron atrophy and subsequent mortality. These mutations exert their harmful effects through a gain of function mechanism, rather than a loss of function. Despite extensive research, the mechanism causing selective motor neuron death still remains unclear. A defining feature of ALS pathogenesis is protein misfolding and aggregation, evidenced by ubiquitinated protein inclusions containing SOD1 in affected motor neurons. This work aims to identify compounds countering SOD1(A4V) misfolding and aggregation, which could potentially aid in ALS treatment. Methods: The approach employed was in vitro screening of a library comprising 1280 pharmacologically active compounds (LOPAC®) in the context of drug repurposing. Using differential scanning fluorimetry (DSF), these compounds were tested for their impact on SOD1(A4V) thermal stability. Results and Conclusions: Dimer stability was the parameter chosen as the criterion for screening, since the dissociation of the native SOD1 dimer is the step prior to its in vitro aggregation. The screening revealed one compound raising protein-ligand Tm by 6 °C, eleven inducing a higher second Tm, suggesting a stabilization effect, and fourteen reducing Tm from 10 up to 26 °C, suggesting possible interactions or non-specific binding.Keywords
Funding Information
- State Scholarships Foundation (MIS-5000432)
This publication has 216 references indexed in Scilit:
- Effects of PB‐TURSO on the transcriptional and metabolic landscape of sporadic ALS fibroblastsAnnals of Clinical and Translational Neurology, 2022
- Efficacy and Safety of Ultrahigh-Dose Methylcobalamin in Early-Stage Amyotrophic Lateral SclerosisJAMA Neurology, 2022
- Assessment of ligand binding at a site relevant to SOD1 oxidation and aggregationFEBS Letters, 2018
- Analysis of Protein Stability and Ligand Interactions by Thermal Shift AssayCurrent Protocols in Protein Science, 2015
- Recombinant human insulin-like growth factor I (rhIGF-I) for the treatment of amyotrophic lateral sclerosis/motor neuron diseaseCochrane Database of Systematic Reviews, 2012
- A randomized sequential trial of creatine in amyotrophic lateral sclerosisAnnals of Neurology, 2003
- Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALSAnnals of Neurology, 2002
- Effect of ultrahigh-dose methylcobalamin on compound muscle action potentials in amyotrophic lateral sclerosis: A double-blind controlled studyMuscle & Nerve, 1998
- Amyotrophic Lateral SclerosisArchives of Neurology, 1997
- A Double-blind Study of the Effectiveness of Cyclosporine in Amyotrophic Lateral SclerosisArchives of Neurology, 1988